Michael is an Investment Director at BDC, where he is a member of the Services investment team. He holds a degree in English language and literature from Oxford University. Michael joined the firm in 2017, and since joining he has been involved in several transactions, including investments in Prescient Healthcare Group, Fera, DataExpert, SK AeroSafety, Analysys Mason and Achilles, as well as the add-on acquisition of The Kenrich Group for HKA and the subsequent sale of HKA to PAI Partners. Prior to Bridgepoint Development Capital, he was an Associate in the Financial Sponsors Group at HSBC, where he advised private equity clients on several M&A and leveraged finance transactions.
Featured
Building Future-Fit MEX Programs for Modern Pharma Marketing
Discover how modern Marketing Excellence programmes help pharma teams build capability, improve decision-making and deliver greater commercial impact.
News and insights
Featured
What’s Next for Oncology? Strategic Perspectives Following ASCO® 2026
What's next for oncology? Strategic Perspectives Following ASCO 2026
Discover The Prescient Pharma Brand Plan Impact Index
Helping senior leaders strengthen strategy and drive better business performance.
The Four Positioning Challenges Every Pharma Launch Team Must Overcome
Discover four positioning challenges that every pharma launch team should address.
Careers
Work with us
If you're looking to stretch your thinking, lead with purpose, and be part of a culture that values curiosity, accountability and trust, you're in the right place.
